Allt inom Other Corporate Information

Nanexa AB today announces that the European Medicines Agency has approved the company’s clinical trial application for the Phase I study with NEX-22. NEX-22 is a long-acting depot formulation of the GLP-1 analogue liraglutide with Nanexa’s patented PharmaShell® system. The goal is to create a GLP-1 product that can be administered once a month in the treatment of Type 2 diabetes.

Nanexa AB (publ) publishes on Friday, May 3, 2024, its interim report for the first quarter of 2024 and invites to a report commentary.